← 返回

细胞外基质动态在肿瘤免疫调节中的作用:从肿瘤微环境到免疫治疗

英文原题:Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy.

查看英文原题

Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy.

PubMed 2025/06/19(内容时间) J Hematol Oncol Q1 · IF 47.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

细胞外基质(ECM)与肿瘤微环境(TME)的动态变化密切相关,在调节肿瘤免疫中发挥关键作用。ECM在肿瘤进展中的双重作用,包括促进和抑制,归因于其组分影响免疫细胞的激活、迁移和浸润。这一机制与免疫治疗的疗效密切相关。目前,对于ECM重塑如何在空间和时间上与免疫检查点抑制剂(ICIs)或过继性细胞疗法协同作用,理解仍然有限。此外,选择性靶向病理性ECM组分同时保留其稳态功能的策略亟需系统研究。在本综述中,我们总结了目前关于ECM与肿瘤免疫调节之间相互作用的研究发现,特别关注关键ECM组分如何参与免疫调节。此外,我们讨论了靶向ECM相关机制以增强免疫治疗疗效的新兴策略,包括重塑ECM以改善免疫浸润的方法以及与现有免疫治疗协同的策略。通过整合这些见解,我们提供了利用ECM靶向干预克服免疫逃逸并优化癌症免疫治疗结局的视角。

展开英文摘要原文

The extracellular matrix (ECM), closely linked to the dynamic changes in the tumor microenvironment (TME), plays a critical role in modulating tumor immunity. The dual role of the ECM in tumor progression, encompassing both promotion and inhibition, is attributed to its components influencing immune cell activation, migration, and infiltration.

This mechanism is intricately connected with the efficacy of immunotherapies. Currently, there is limited understanding of how ECM remodeling spatially and temporally coordinates with immune checkpoint inhibitors (ICIs) or adoptive cell therapies.

Furthermore, strategies to selectively target pathological ECM components while preserving their homeostatic functions urgently require systematic investigation. In this review, we summarize current findings on the interplay between ECM and tumor immune regulation, with a particular focus on how key ECM components contribute to immune modulation.

Furthermore, we discuss emerging strategies targeting ECM-related mechanisms to enhance the efficacy of immunotherapies, including approaches that remodel the ECM to improve immune infiltration and strategies that synergize with existing immunotherapies. By integrating these insights, we provide a perspective on leveraging ECM-targeted interventions to overcome immune evasion and optimize cancer immunotherapy outcomes.

论文信息

作者
Hu Q、Zhu Y、Mei J、Liu Y、Zhou G
第一作者单位
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, People's Republic of China.China
通讯作者单位
The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, People's Republic of China. zhouguoren888@126.com.China
文献类型
综述 · 非美国政府资助研究
期刊
Journal of hematology & oncology2025 Jun 19
原文标识
PubMed 40537775 · DOI 10.1186/s13045-025-01717-y